Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome

Scott W. Woods, Alan Breier, Robert B. Zipursky, Diana O. Perkins, Jean Addington, Tandy J. Miller, Keith A. Hawkins, Eva Marquez, Stacy R. Lindborg, Mauricio Tohen, Thomas H. McGlashan

Research output: Contribution to journalArticle

168 Citations (Scopus)

Abstract

Background: The prodromal phase of schizophrenic disorders has been described prospectively. The present study aimed to determine the short-term efficacy and safety of olanzapine treatment of prodromal symptoms compared with placebo. Methods: This was a double-blind, randomized, parallel-groups, placebo-controlled trial with fixed-flexible dosing conducted at four sites. Sixty patients met prodromal diagnostic criteria, including attenuated psychotic symptoms, as determined by structured interviews. Olanzapine 5-15 mg daily or placebo was prescribed for 8 weeks. Results: In the mixed-effects, repeated-measures analysis, the treatment × time interaction for the change from baseline on the Scale of Prodromal Symptoms total score was statistically significant, and post hoc analyses revealed that the olanzapine-placebo difference reached p <.10 by week 6 and p <.05 at week 8. Ratings of extrapyramidal symptoms remained low in each group and were not significantly different. Olanzapine patients gained 9.9 lb versus .7 lb for placebo patients (p <.001). Conclusions: This short-term analysis suggests olanzapine is associated with significantly greater symptomatic improvement but significantly greater weight gain than is placebo in prodromal patients. Extrapyramidal symptoms with olanzapine were minimal and similar to those with placebo. Future research over the longer term with more patients will be needed before recommendations can be made regarding routine treatment.

Original languageEnglish (US)
Pages (from-to)453-464
Number of pages12
JournalBiological Psychiatry
Volume54
Issue number4
DOIs
StatePublished - Aug 15 2003

Fingerprint

olanzapine
Placebos
Prodromal Symptoms
Therapeutics
Weight Gain
Schizophrenia

Keywords

  • Olanzapine
  • Placebo
  • Prodrome
  • Scale Of Prodromal Symptoms
  • Schizophrenia
  • Structured Interview for Prodromal Syndromes

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Woods, S. W., Breier, A., Zipursky, R. B., Perkins, D. O., Addington, J., Miller, T. J., ... McGlashan, T. H. (2003). Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry, 54(4), 453-464. https://doi.org/10.1016/S0006-3223(03)00321-4

Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. / Woods, Scott W.; Breier, Alan; Zipursky, Robert B.; Perkins, Diana O.; Addington, Jean; Miller, Tandy J.; Hawkins, Keith A.; Marquez, Eva; Lindborg, Stacy R.; Tohen, Mauricio; McGlashan, Thomas H.

In: Biological Psychiatry, Vol. 54, No. 4, 15.08.2003, p. 453-464.

Research output: Contribution to journalArticle

Woods, SW, Breier, A, Zipursky, RB, Perkins, DO, Addington, J, Miller, TJ, Hawkins, KA, Marquez, E, Lindborg, SR, Tohen, M & McGlashan, TH 2003, 'Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome', Biological Psychiatry, vol. 54, no. 4, pp. 453-464. https://doi.org/10.1016/S0006-3223(03)00321-4
Woods, Scott W. ; Breier, Alan ; Zipursky, Robert B. ; Perkins, Diana O. ; Addington, Jean ; Miller, Tandy J. ; Hawkins, Keith A. ; Marquez, Eva ; Lindborg, Stacy R. ; Tohen, Mauricio ; McGlashan, Thomas H. / Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. In: Biological Psychiatry. 2003 ; Vol. 54, No. 4. pp. 453-464.
@article{566e4736eebe498a99ee950ad32c49c3,
title = "Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome",
abstract = "Background: The prodromal phase of schizophrenic disorders has been described prospectively. The present study aimed to determine the short-term efficacy and safety of olanzapine treatment of prodromal symptoms compared with placebo. Methods: This was a double-blind, randomized, parallel-groups, placebo-controlled trial with fixed-flexible dosing conducted at four sites. Sixty patients met prodromal diagnostic criteria, including attenuated psychotic symptoms, as determined by structured interviews. Olanzapine 5-15 mg daily or placebo was prescribed for 8 weeks. Results: In the mixed-effects, repeated-measures analysis, the treatment × time interaction for the change from baseline on the Scale of Prodromal Symptoms total score was statistically significant, and post hoc analyses revealed that the olanzapine-placebo difference reached p <.10 by week 6 and p <.05 at week 8. Ratings of extrapyramidal symptoms remained low in each group and were not significantly different. Olanzapine patients gained 9.9 lb versus .7 lb for placebo patients (p <.001). Conclusions: This short-term analysis suggests olanzapine is associated with significantly greater symptomatic improvement but significantly greater weight gain than is placebo in prodromal patients. Extrapyramidal symptoms with olanzapine were minimal and similar to those with placebo. Future research over the longer term with more patients will be needed before recommendations can be made regarding routine treatment.",
keywords = "Olanzapine, Placebo, Prodrome, Scale Of Prodromal Symptoms, Schizophrenia, Structured Interview for Prodromal Syndromes",
author = "Woods, {Scott W.} and Alan Breier and Zipursky, {Robert B.} and Perkins, {Diana O.} and Jean Addington and Miller, {Tandy J.} and Hawkins, {Keith A.} and Eva Marquez and Lindborg, {Stacy R.} and Mauricio Tohen and McGlashan, {Thomas H.}",
year = "2003",
month = "8",
day = "15",
doi = "10.1016/S0006-3223(03)00321-4",
language = "English (US)",
volume = "54",
pages = "453--464",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome

AU - Woods, Scott W.

AU - Breier, Alan

AU - Zipursky, Robert B.

AU - Perkins, Diana O.

AU - Addington, Jean

AU - Miller, Tandy J.

AU - Hawkins, Keith A.

AU - Marquez, Eva

AU - Lindborg, Stacy R.

AU - Tohen, Mauricio

AU - McGlashan, Thomas H.

PY - 2003/8/15

Y1 - 2003/8/15

N2 - Background: The prodromal phase of schizophrenic disorders has been described prospectively. The present study aimed to determine the short-term efficacy and safety of olanzapine treatment of prodromal symptoms compared with placebo. Methods: This was a double-blind, randomized, parallel-groups, placebo-controlled trial with fixed-flexible dosing conducted at four sites. Sixty patients met prodromal diagnostic criteria, including attenuated psychotic symptoms, as determined by structured interviews. Olanzapine 5-15 mg daily or placebo was prescribed for 8 weeks. Results: In the mixed-effects, repeated-measures analysis, the treatment × time interaction for the change from baseline on the Scale of Prodromal Symptoms total score was statistically significant, and post hoc analyses revealed that the olanzapine-placebo difference reached p <.10 by week 6 and p <.05 at week 8. Ratings of extrapyramidal symptoms remained low in each group and were not significantly different. Olanzapine patients gained 9.9 lb versus .7 lb for placebo patients (p <.001). Conclusions: This short-term analysis suggests olanzapine is associated with significantly greater symptomatic improvement but significantly greater weight gain than is placebo in prodromal patients. Extrapyramidal symptoms with olanzapine were minimal and similar to those with placebo. Future research over the longer term with more patients will be needed before recommendations can be made regarding routine treatment.

AB - Background: The prodromal phase of schizophrenic disorders has been described prospectively. The present study aimed to determine the short-term efficacy and safety of olanzapine treatment of prodromal symptoms compared with placebo. Methods: This was a double-blind, randomized, parallel-groups, placebo-controlled trial with fixed-flexible dosing conducted at four sites. Sixty patients met prodromal diagnostic criteria, including attenuated psychotic symptoms, as determined by structured interviews. Olanzapine 5-15 mg daily or placebo was prescribed for 8 weeks. Results: In the mixed-effects, repeated-measures analysis, the treatment × time interaction for the change from baseline on the Scale of Prodromal Symptoms total score was statistically significant, and post hoc analyses revealed that the olanzapine-placebo difference reached p <.10 by week 6 and p <.05 at week 8. Ratings of extrapyramidal symptoms remained low in each group and were not significantly different. Olanzapine patients gained 9.9 lb versus .7 lb for placebo patients (p <.001). Conclusions: This short-term analysis suggests olanzapine is associated with significantly greater symptomatic improvement but significantly greater weight gain than is placebo in prodromal patients. Extrapyramidal symptoms with olanzapine were minimal and similar to those with placebo. Future research over the longer term with more patients will be needed before recommendations can be made regarding routine treatment.

KW - Olanzapine

KW - Placebo

KW - Prodrome

KW - Scale Of Prodromal Symptoms

KW - Schizophrenia

KW - Structured Interview for Prodromal Syndromes

UR - http://www.scopus.com/inward/record.url?scp=0142011201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142011201&partnerID=8YFLogxK

U2 - 10.1016/S0006-3223(03)00321-4

DO - 10.1016/S0006-3223(03)00321-4

M3 - Article

C2 - 12915290

AN - SCOPUS:0142011201

VL - 54

SP - 453

EP - 464

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 4

ER -